Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apPHOTAC-II-2C: sourced facts only. name: "This approach was extended to synthesize apPHOTAC-II-2C, the first nanomolar photoswitchable degrader of tumor-associated protein MTH1, establishing a promising synthetic approach for future PHOTAC development." [PMID:42807851]; target: "This approach was extended to synthesize apPHOTAC-II-2C, the first nanomolar photoswitchable degrader of tumor-associated protein MTH1, establishing a promising synthetic approach for future PHOTAC development." [PMID:42807851]; developer: "Department of Chemistry, School of Arts & Sciences, University of Pennsylvania Philadelphia PA USA [email protected]." [PMID:42807851]; modality: "This approach was extended to synthesize apPHOTAC-II-2C, the first nanomolar photoswitchable degrader of tumor-associated protein MTH1, establishing a promising synthetic approach for future PHOTAC development." [PMID:42807851]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apPHOTAC-II-2C.